Nordea Investment Management AB reduced its holdings in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 40.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,500 shares of the biotechnology company’s stock after selling 30,587 shares during the quarter. Nordea Investment Management AB owned 0.31% of Anika Therapeutics worth $2,245,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ANIK. Wells Fargo & Company MN grew its position in shares of Anika Therapeutics by 891.4% during the first quarter. Wells Fargo & Company MN now owns 166,674 shares of the biotechnology company’s stock worth $7,240,000 after buying an additional 149,862 shares in the last quarter. Great West Life Assurance Co. Can raised its holdings in Anika Therapeutics by 10.3% in the first quarter. Great West Life Assurance Co. Can now owns 21,220 shares of the biotechnology company’s stock valued at $921,000 after acquiring an additional 1,974 shares in the last quarter. First Trust Advisors LP raised its holdings in Anika Therapeutics by 11.9% in the first quarter. First Trust Advisors LP now owns 13,245 shares of the biotechnology company’s stock valued at $575,000 after acquiring an additional 1,410 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Anika Therapeutics by 7.5% in the first quarter. Bank of New York Mellon Corp now owns 277,378 shares of the biotechnology company’s stock valued at $12,049,000 after acquiring an additional 19,457 shares in the last quarter. Finally, Comerica Bank raised its holdings in Anika Therapeutics by 4.3% in the first quarter. Comerica Bank now owns 16,519 shares of the biotechnology company’s stock valued at $756,000 after acquiring an additional 685 shares in the last quarter. Institutional investors own 84.47% of the company’s stock.

Anika Therapeutics Inc. (NASDAQ:ANIK) opened at 58.81 on Tuesday. The company has a market cap of $862.04 million, a P/E ratio of 26.13 and a beta of 1.66. The firm’s 50-day moving average price is $54.90 and its 200-day moving average price is $48.71. Anika Therapeutics Inc. has a 12-month low of $41.38 and a 12-month high of $59.32.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.32. The firm had revenue of $33.50 million during the quarter, compared to the consensus estimate of $27.20 million. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The business’s revenue was up 25.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.57 EPS. Analysts expect that Anika Therapeutics Inc. will post $2.20 EPS for the current year.

In other Anika Therapeutics news, CEO Charles H. Sherwood sold 63,799 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.79, for a total value of $3,240,351.21. Following the completion of the sale, the chief executive officer now owns 174,705 shares in the company, valued at approximately $8,873,266.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Charles H. Sherwood sold 14,201 shares of Anika Therapeutics stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $50.03, for a total value of $710,476.03. Following the sale, the chief executive officer now directly owns 246,740 shares in the company, valued at approximately $12,344,402.20. The disclosure for this sale can be found here. Insiders own 6.57% of the company’s stock.

WARNING: “Anika Therapeutics Inc. (ANIK) Shares Sold by Nordea Investment Management AB” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/03/anika-therapeutics-inc-anik-shares-sold-by-nordea-investment-management-ab.html.

ANIK has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Anika Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. BidaskClub raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 8th.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Stock Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related stocks with our FREE daily email newsletter.